The healthcare and pharmaceutical industries have been undergoing a period of rapid change over the last decade, due to the impact of ageing populations and the rise of new and more targeted medical needs.
In this evolving scenario, Dompé is a biopharmaceutical company committed to the development of innovative treatment solutions for rare and often orphan diseases in areas with unmet treatment needs, such as diabetes, organ transplants, ophthalmology and oncology.
Dompé pursues this objective by promoting and actively participating in a network made up of the best names in each activity of the pharmaceutical industry, from research to development and from production to marketing.
With a unique vision and team-driven approach, Eugenio Aringhieri – CEO of Dompé, which is based in Italy – has promoted the group’s functional reorganisation and given impulse to its industrial strategy with the aim of making Dompé an internationally recognised science-based company. Founded in 1940, Dompé has its headquarters in Milan, major industrial and biotechnological research facilities in L’Aquila, and an R&D unit in Naples. As part of its international development strategy, the company has offices across the world – in New York, Paris, London, Berlin, Barcelona and Tirana.
Overseeing the company’s rapid expansion, Aringhieri is considered a highly motivated and innovative visionary with a strong business head on his shoulders. Unafraid of making major strategic and functional changes to the group and its processes, Aringhieri is widely regarded as a stalwart within the industry and an expert in managing change. This is a key feature for an organisation in the biotech industry, and the firm is in an excellent position with a self-starter of this nature at the helm. Aringhieri has long been recognised as an opinion leader in the biotech field, and is also President of Farmindustria’s Biotech Group, the Italian Association of pharmaceutical companies.